Recent FDA approvals and changes.
出版信息
AIDS Patient Care STDS. 2010 Feb;24(2):133-4. doi: 10.1089/apc.2010.9911.
PMID:20156092
Abstract
摘要
相似文献
1
Recent FDA approvals and changes.
AIDS Patient Care STDS. 2010 Feb;24(2):133-4. doi: 10.1089/apc.2010.9911.
2
[HIV therapy and adherence].
MMW Fortschr Med. 2008 Apr 28;150 Spec No 1:62-3.
3
4
Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?
Expert Opin Pharmacother. 2007 Feb;8(3):371-82. doi: 10.1517/14656566.8.3.371.
5
Recent FDA approvals and changes.
AIDS Patient Care STDS. 2010 May;24(5):342. doi: 10.1089/apc.2010.9905.
6
FDA notifications. Generic efavirenz/emtricitabine/fenofovir has tentative approval.
AIDS Alert. 2009 Oct;24(10):119-20.
7
No changes in efavirenz plasma concentrations in HIV-infected patients who switch from Stocrin to Atripla.
J Acquir Immune Defic Syndr. 2010 Aug;54(5):e12-3. doi: 10.1097/QAI.0b013e3181ed1896.
8
A once-daily combination tablet (Atripla) for HIV.
Med Lett Drugs Ther. 2006 Sep 25;48(1244):78-9.
9
Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet.
Drugs. 2006;66(11):1501-12; discussion 1513-4. doi: 10.2165/00003495-200666110-00012.
10
New once-daily HIV combination better tolerated.
Expert Rev Anti Infect Ther. 2004 Dec;2(6):826.
Zotero 插件